Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




May
18
Today In Oncology
Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age
FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2 Positive Early Breast Cancer
Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience
Advanced Prostate Cancer Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide
Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo